Amicus Repositions With A Focus On Combining Chaperones With ERTs

Biotech re-obtains all rights to migalastat from GSK, buys out ERT specialist Callidus and will raise $40 million through a private placement and a debt financing. Callidus co-founder, a former Genzyme scientist, will take over the Amicus’ scientific team, while the company slashes its overall headcount by 14%.

After losing its big pharma partner, GlaxoSmithKline PLC, Amicus Therapeutics Inc. has gone on the offensive to reposition itself as a “bio-betters” developer by acquiring enzyme replacement therapy (ERT) start-up Callidus Biopharma Inc.and reorganizing its financial and corporate structure.

An investor call and two separate press releases were required to encapsulate all of the news coming out of Amicus...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America